ASH 2020 | TLS in patients with CLL treated with venetoclax
William Wierda
• 1 Dec 2020
William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of a retrospective study investigating rates of tumor lysis syndrome (TLS) and outcomes for patients with chronic lymphocytic leukemia (CLL) treated with venetoclax in clinical trial and post-marketing settings. The potent pro-apoptotic effect of venetoclax on CLL cells means that venetoclax treatment poses a risk of inducing TLS. With current mitigation measures, the incidence of TLS was 1.8%, indicating that mitigation measures successfully mitigated TLS for patients being treated with venetoclax. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
